Estudo randomizado de fase 2 | Eficácia do epigalocatecina-3-galato na prevenção de dermatites em pacientes com câncer de mama sob radioterapia pós-cirúrgica.
6 Jun, 2022 | 11:11hEfficacy of Epigallocatechin-3-Gallate in Preventing Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy: A Double-Blind, Placebo-Controlled, Phase 2 Randomized Clinical Trial – JAMA Dermatology (gratuito por tempo limitado)
Resumo visual: Efficacy of Epigallocatechin-3-Gallate on Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy